CIBC Asset Management Inc Has $18.78 Million Stock Holdings in AstraZeneca PLC $AZN

CIBC Asset Management Inc boosted its stake in AstraZeneca PLC (NASDAQ:AZN) by 2.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 244,724 shares of the company’s stock after buying an additional 6,635 shares during the period. CIBC Asset Management Inc’s holdings in AstraZeneca were worth $18,775,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of AZN. Fayez Sarofim & Co boosted its holdings in shares of AstraZeneca by 173.4% during the second quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock worth $261,764,000 after acquiring an additional 2,376,032 shares during the period. Valeo Financial Advisors LLC lifted its holdings in AstraZeneca by 14,797.3% during the 2nd quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after purchasing an additional 2,307,047 shares during the last quarter. Acadian Asset Management LLC boosted its stake in AstraZeneca by 2,389.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock valued at $142,798,000 after purchasing an additional 1,961,764 shares during the period. Jennison Associates LLC grew its holdings in AstraZeneca by 15.2% in the 2nd quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock valued at $850,255,000 after buying an additional 1,605,133 shares in the last quarter. Finally, Raymond James Financial Inc. grew its holdings in AstraZeneca by 64.8% in the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock valued at $264,373,000 after buying an additional 1,487,662 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a report on Friday, January 16th. Jefferies Financial Group initiated coverage on shares of AstraZeneca in a research report on Monday, October 27th. They set a “buy” rating on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday. Barclays restated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Finally, TD Cowen reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $92.95 on Monday. The firm has a 50 day moving average of $91.87 and a 200-day moving average of $83.68. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $96.51. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $288.31 billion, a PE ratio of 30.88, a PEG ratio of 1.59 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The business had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. During the same period last year, the firm posted $2.08 earnings per share. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. On average, equities research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.